Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glioma, Astrocytic Clear all
Completed Phase 1 Interventional

Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma

NCT00357253
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
capecitabine, radiation therapy
Drug · Radiation
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

NCT00006024
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
lomustine, temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 4, 2026, 5:10 PM EDT
Recruiting Phase 1 Interventional

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NCT03911388
View directory record Official record
Conditions
Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms, Astrocytoma, Astrocytoma, Cerebellar, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Cerebellar PNET, Childhood, Cerebellar Neoplasms, Cerebellar Neoplasms, Primary, Cerebellar Neoplasm, Malignant, Cerebellar Neoplasm Malignant Primary, Neoplasm Metastases, Neoplasm Malignant, Neoplasms, Neuroepithelial, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Central Nervous System Neoplasms, Primary, Central Nervous System Neoplasms, Malignant, Nervous System Neoplasms, Neoplasms by Site, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Medulloblastoma Recurrent, HSV, Virus, Pediatric Brain Tumor, Nervous System Cancer, Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Interventions
G207
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months to 22 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas

NCT00597402
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Brain Tumor
Interventions
Avastin, Temozolomide, Radiation Therapy (XRT), Irinotecan
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

NCT00610571
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions
Oral Topotecan and Temodar
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

NCT00326664
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma
Interventions
Cediranib Maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00014677
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
interleukin-4 PE38KDEL cytotoxin, conventional surgery
Biological · Procedure
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
La Jolla, California • Atlanta, Georgia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 4, 2026, 5:10 PM EDT
Active, not recruiting Phase 2 Interventional

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

NCT03919071
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions
Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
130
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

NCT01723020
View directory record Official record
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Glioblastoma, Multiple Myeloma
Interventions
AMG 232
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Santa Monica, California • Norwalk, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Cancer Stem Cell High-Throughput Drug Screening Study

NCT02654964
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Combination Drug Therapy
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 4, 2026, 5:10 PM EDT
Recruiting Phase 2 Interventional

Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial

NCT06835803
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
Dose-escalated radiation therapy, Standard hypofractionated radiation
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 4, 2026, 5:10 PM EDT
Active, not recruiting Early Phase 1 Interventional

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

NCT02933736
View directory record Official record
Conditions
Glioblastoma Multiforme, Meningioma
Interventions
Ribociclib
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 4, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional

Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme

NCT00238277
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, adjuvant therapy, chemotherapy, radiation therapy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

NCT01435395
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide, bevacizumab and bortezomib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 4, 2026, 5:10 PM EDT
Not yet recruiting Not applicable Interventional

GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma

NCT07852975
View directory record Official record
Conditions
Recurrent Glioma (Glioblastoma Multiforme)
Interventions
Arm 1 will use Ketone supplement 80 gm daily, Arm 2 will follow Ketogenic Diet 7 days leading up to the clinically indicated surgery.
Dietary Supplement · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 111 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors

NCT00002619
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, carboplatin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 4, 2026, 5:10 PM EDT
Terminated Phase 1 Interventional

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

NCT00112619
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 4, 2026, 5:10 PM EDT
Withdrawn Not applicable Interventional

Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy

NCT01233479
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
systemic chemotherapy, laboratory biomarker analysis, therapeutic surgical procedure, radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
4 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 4, 2026, 5:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

NCT01884740
View directory record Official record
Conditions
Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma, Pilomyxoid Astrocytoma, Mixed Oligodendroglioma-Astrocytoma, Brain Stem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
SIACI of Erbitux and Bevacizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 4, 2026, 5:10 PM EDT
Withdrawn Phase 1 Interventional

Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

NCT02055196
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
carboxylesterase-expressing allogeneic neural stem cells, irinotecan hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 4, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemoradiation for Resectable Glioblastoma

NCT04209790
View directory record Official record
Conditions
Glioblastoma, Surgery, High Grade Glioma
Interventions
Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)
Radiation · Drug · Procedure
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 4, 2026, 5:10 PM EDT
Not yet recruiting Phase 1 Interventional

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

NCT07385846
View directory record Official record
Conditions
Glioblastoma, Mismatch Repair Deficiency
Interventions
Pembrolizumab, Navifus Focused Ultrasound Sonification
Drug · Device
Lead sponsor
Jennifer Leddon
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 4, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

NCT00003348
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 4, 2026, 5:10 PM EDT